## Tan A Ince

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7331700/publications.pdf

Version: 2024-02-01

16 papers	1,583 citations	643344 15 h-index	1051228 16 g-index
10	1.0	1.0	2577
18 all docs	18 docs citations	18 times ranked	3577 citing authors

#	Article	IF	CITATIONS
1	HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene, 2019, 38, 6599-6614.	2.6	82
2	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. Clinical Cancer Research, 2018, 24, 4874-4886.	3.2	60
3	<scp>VEGFA</scp> activates an epigenetic pathway upregulating ovarian cancerâ€initiating cells. EMBO Molecular Medicine, 2017, 9, 304-318.	3.3	63
4	Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4184-E4192.	3.3	104
5	Label-free tumor cell detection and differentiation based on electrical impedance spectroscopy. , 2016,		7
6	Reference-free deconvolution of DNA methylation data and mediation by cell composition effects. BMC Bioinformatics, 2016, 17, 259.	1.2	202
7	Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Research and Treatment, 2016, 157, 77-90.	1.1	52
8	Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Research and Treatment, 2016, 158, 113-126.	1.1	79
9	Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b–Mediated Malignant Progression. Cancer Research, 2016, 76, 491-504.	0.4	142
10	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 935-947.	3.2	42
11	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCl Insight, $2016,1,.$	2.3	45
12	Of Mice and Women: A Comparative Tissue Biology Perspective of Breast Stem Cells and Differentiation. Journal of Mammary Gland Biology and Neoplasia, 2015, 20, 51-62.	1.0	44
13	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 2015, 6, 7419.	5.8	149
14	Normal Cell-Type Epigenetics and Breast Cancer Classification: A Case Study of Cell Mixture–Adjusted Analysis of DNA Methylation Data from Tumors. Cancer Informatics, 2014, 13s4, CIN.S13980.	0.9	16
15	Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <i>In Vitro</i> and <i>In Vivo</i> Clinical Cancer Research, 2012, 18, 5911-5923.	3.2	69
16	The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics and Gynecology, 2007, 19, 3-9.	0.9	425